(Q37801062)

23 August 2017

title

Pharmacologic therapy for the neurogenic bladder (English)

1 reference

23 August 2017

1 reference

Anne P Cameron

1

1 reference

23 August 2017

publication date

11 August 2010

1 reference

Urologic Clinics of North America

23 August 2017

published in

1 reference

23 August 2017

volume

37

1 reference

23 August 2017

issue

4

1 reference

23 August 2017

page(s)

495-506

1 reference

Women with voiding dysfunction secondary to bladder outlet dyssynergia in the setting of multiple sclerosis do not demonstrate significantly elevated intravesical pressures

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Treatment of detrusor hyperreflexia in multiple sclerosis: a double-blind, crossover clinical trial comparing methantheline bromide (Banthine), flavoxate chloride (Urispas) and meladrazine tartrate (Lisidonil).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Expression and distribution of cholinergic receptors in the human urothelium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

EAU guidelines on neurogenic lower urinary tract dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Current practice patterns in the urologic surveillance and management of patients with spinal cord injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Anticholinergics for urinary symptoms in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Dose-ranging study of tolterodine in patients with detrusor hyperreflexia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Human Idiopathic and Neurogenic Overactive Bladders and the Role of M2 Muscarinic Receptors in Contraction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

The M2 muscarinic receptor mediates contraction through indirect mechanisms in mouse urinary bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Selective alkylation of rat urinary bladder muscarinic receptors with 4-DAMP mustard reveals a contractile function for the M2 muscarinic receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Blood-brain barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Effect of intermittent urethral catheterization and oxybutynin bladder instillation on urinary continence status and quality of life in a selected group of spinal cord injury patients with neuropathic bladder dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Combined intravesical and oral oxybutynin chloride in adult patients with spinal cord injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Tolterodine--a new bladder-selective antimuscarinic agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Long-term efficacy and safety of tolterodine in children with neurogenic detrusor overactivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Comparative efficacy and safety of extended-release and instant-release tolterodine in children with neural tube defects having cystometric abnormalities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Trospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Efficacy, tolerability and safety of propiverine hydrochloride in children and adolescents with congenital or traumatic neurogenic detrusor overactivity--a retrospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Novel role for alpha1-adrenergic receptor subtypes in lower urinary tract symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Alpha1-adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding alpha1-adrenergic receptor subtypes at four distinct levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

The density of cholinergic and alpha and beta adrenergic receptors in the normal and hyper-reflexic human detrusor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Effect of doxazosin on stretch-activated adenosine triphosphate release in bladder urothelial cells from patients with benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Reduction of bladder contractility after alpha-adrenergic blockade and after ganglionic blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Prazosin treatment of neurological patients with detrusor hyperreflexia and bladder emptying disability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Urodynamic effects of alpha1-blocker tamsulosin on voiding dysfunction in patients with neurogenic bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Effect of intravenous alfuzosin on urethral pressure in patients with neurogenic bladder dysfunction. DORALI Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

A study of the alpha-1 adrenoceptor blocker prazosin in the prophylactic management of autonomic dysreflexia in high spinal cord injury patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Pharmacotherapy for neurogenic detrusor overactivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Pathophysiology of autonomic dysreflexia: long-term treatment with terazosin in adult and paediatric spinal cord injury patients manifesting recurrent dysreflexic episodes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Analysis of the anticholinergic and musculotropic effects of desmethylimipramine on the rabbit urinary bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

The pharmacology of paediatric incontinence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

The role of imipramine therapy in bladder exstrophy after bladder neck reconstruction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Urodynamics-based evidence for the beneficial effect of imipramine on valve bladders in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Comparative tolerability of drug therapies used to treat incontinence and enuresis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Nocturnal enuresis: a placebo controlled trial of two antidepressant drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Combined pharmacotherapy for nocturnal enuresis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Triple therapy in refractory detrusor overactivity: a preliminary study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Beta3-adrenoceptors in human detrusor muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

The effects of a new selective beta3-adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Emerging drugs for treatment of overactive bladder and detrusor overactivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Vanilloid receptors: new insights enhance potential as a therapeutic target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Mechanisms underlying the recovery of lower urinary tract function following spinal cord injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Capsaicin and neurogenic detrusor hyperreflexia: a double-blind placebo-controlled study in 20 patients with spinal cord lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Neurotoxin treatments for urinary incontinence in subjects with spinal cord injury or multiple sclerosis: a systematic review of effectiveness and adverse effects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Purinoceptors as therapeutic targets for lower urinary tract dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Expression of purinergic P2X2-receptors in neurogenic bladder dysfunction due to spinal cord injury: a preliminary immunohistochemical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Serotonin-induced potentiation of cholinergic responses to electrical field stimulation in normal and neurogenic overactive human detrusor muscle.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Effects of milnacipran and paroxetine on overactive bladder due to neurologic diseases: a urodynamic assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Effect of antiepileptic agent, levetiracetam, on urodynamic parameters and neurogenic bladder overactivity in chronically paraplegic rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Gabapentin Treatment of Neurogenic Overactive Bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Nitric oxide-mediated suppression of detrusor overactivity by arginase inhibitor in rats with chronic spinal cord injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Therapeutic effects of endothelin-A receptor antagonist on bladder overactivity in rats with chronic spinal cord injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

Microvascular and neuronal consequences of common carotid artery thrombosis and platelet embolization in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

inferred from DOI database lookup

7 January 2021

based on heuristic

Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2010.06.004

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.UCL.2010.06.004

1 reference

23 August 2017

1 reference